What is the effectiveness of the lipid lowering agent SAR236553 compared to placebo on the occurrence of cardiovascular events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) in patients who have experienced an acute coronary syndrome (ACS) event 4 to 16 weeks prior to randomization and are treated with intensive statin therapy

Consenting patients will be randomized into two arms. The intervention arm will receive SAR236553 - 75mg/150mg as a subcutaneous injection every two weeks until a study end-point is reached. It is expected that that each patient will receive the allocated treatment for at least 24 months.

The cotrol arm will receive a standardized placebo as a subcutaneous injection every two weeks for (please give duration).

Standard therapy will be continued for both arms.

1. Recent acute coronary syndrome (4-16 weeks prior to randomization)
2. On intensive statin therapy (defined as atorvastatin 40 or 80 mg, or rosuvastatin 20 or 40 mg) or at maximally tolerated dose of these given statins, or other non statin LMT(s).
3. Patients not adequately controlled (as defined by at least one of the following: LDL-C ? 70 mg/dL [?1.81 mmol/L], ApoB ?80 mg/dL [?0.8 mmol/L], or non-HDL-C ?100 mg/dL [?2.59 mmol/L]) at the the qualifying Visit (V2), despite evidence-based lipid lowering therapy (including intensive atorvastatin/rosuvastatin therapy or maximally tolerated dose of either of these 2 statins, or other non statin LMTs).
4. Signed written informed consent.

1. All of the following: LDL-C <70 mg/dL (<1.81 mmol/L), ApoB < 80 mg/dL (< 0.8 mmol/L), and non-HDL-C <100 mg/dL (<2.59 mmol/L) at the qualifying Visit (V2).
2. Age <40 years.
3. Patients who have experienced an ACS event more than 16 weeks (+ 3 days) prior to randomization visit (V3).
4. Not on a stable dose of atorvastatin or rosuvastatin for at least 2 weeks prior to qualifying visit (V2 or V2b) and at least 4 weeks prior to randomization visit (V3), or not on a stable dose of any other authorized LMT for at least 4 weeks prior to qualifying visit (V2 or V2b) and at least 6 weeks prior to randomization visit (V3, Month 0).
5. Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg) at V2 or V3.
6. New York Heart Association Class III or IV congestive heart failure persisting despite treatment or if measured LVEF <25%.
7. Known history of hemorrhagic stroke.
8. Fasting serum triglycerides (TG) >400 mg/dL (>4.52 mmol/L) prior to randomization.
9. Known history of untreated hypothyroidism.
10. Patient who has been previously treated with at least one dose of SAR236553 or any other anti-PCSK9 monoclonal antibody in other clinical trials.

11. Laboratory findings measured during screening and before randomization visit: Positive test for hepatitis B surface antigen and/or hepatitis C antibody, Triglycerides (TG) > 400mg/dL (>4.52 mmol/L) (1 repeat lab allowed), Positive serum or urine pregnancy test in females of childbearing potential, eGFR <30 mL/min/1.73 m² according to 4-variable MDRD Study equation (calculated by central lab), ALT or AST >3 x ULN on most recent determination prior to randomization (1 repeat lab is allowed), CPK >3 x ULN on most recent determination prior to randomization (1 repeat lab is allowed).

12. Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases, patients with short life expectancy.

13. Patients considered by the Investigator or any sub-Investigator as inappropriate for this study for any reason, eg: •Those deemed unable to meet specific protocol requirements, such as scheduled visits. •Investigator or any sub-Investigator, pharmacist, study coordinator, other study staff or relative thereof directly involved in the conduct of the protocol, etc. •Presence of any other conditions (eg, geographic, social….) actual or anticipated, that the Investigator feels would restrict or limit the patient’s participation for the duration of the study